Regional Manager - Prenatal, Central/Southern Illinois

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Molecular Diagnostics, Healthcare, Biotechnology, Medical DevicesIndustries

Requirements

Candidates must have a minimum of 4 years of field sales management experience in molecular diagnostics or genetics, specifically within Women's Health, Prenatal, or Reproductive Health. Experience selling directly to OBGYNs, MFMs, Genetic Counselors, and hospitals/IDNs in the Central/Southern Illinois region is required, along with an existing portfolio of client relationships. Proven success in hiring, developing, coaching, and motivating sales teams to exceed goals is essential. Demonstrated sales track record, strong negotiation and closing skills, data analysis proficiency, and excellent organizational and communication skills are also necessary.

Responsibilities

The Regional Manager will develop and execute a data-driven sales strategy for the Central/Southern Illinois region. They will build, lead, and develop a team of sales representatives to achieve sales strategies and optimize market share. Responsibilities include recruiting, hiring, training, and managing the sales team. The manager will also develop customized pitches for healthcare providers, analyze sales data to identify trends and competition, and present clinical information to clients and internal teams.

Skills

Clinical Sales Management

Sales Strategy

Business Development

Team Leadership

Molecular Diagnostics

Prenatal Diagnostics

Cancer Diagnostics

OBGYN

MFM

Lab Diagnostics

Sales Planning

Market Development

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters

2016Year Founded

$380.2MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.

Rapid technological advancements may render their current technology obsolete.

Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.

Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.

They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.

Their new Austin facility will create 1,000 jobs, boosting production and local economy.

Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI

Try Jobo Free